A Goertz

407 total citations
13 papers, 246 citations indexed

About

A Goertz is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, A Goertz has authored 13 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Epidemiology, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Hepatology. Recurrent topics in A Goertz's work include Diabetes Treatment and Management (4 papers), Hepatitis Viruses Studies and Epidemiology (3 papers) and Food Allergy and Anaphylaxis Research (2 papers). A Goertz is often cited by papers focused on Diabetes Treatment and Management (4 papers), Hepatitis Viruses Studies and Epidemiology (3 papers) and Food Allergy and Anaphylaxis Research (2 papers). A Goertz collaborates with scholars based in Germany, United Kingdom and Australia. A Goertz's co-authors include Peter Wutzler, Kurt Banz, Stefan Wagenpfeil, U Reitberger, Holger Stammer, A Neiss, Jens Vollmar, A. Neiß, Beate Wieseler and Thomas Hammerschmidt and has published in prestigious journals such as Vaccine, Value in Health and PharmacoEconomics.

In The Last Decade

A Goertz

13 papers receiving 236 citations

Peers

A Goertz

EPIDE

EDM

HEPAT

EE

PARAS

Benedetto Simone Italy

Shaia Almalki Saudi Arabia

Turner Tb

Sonia Gutiérrez Spain

V. Hingorani India

Nicholas Ngomi Kenya

Iain Tatt United Kingdom

Ross Murtagh Ireland

Ángel Hernández Merino Spain

David A. Forero‐Peña Venezuela

Benedetto Simone Italy

A Goertz

134 ×1.1

EPIDE

10 ×0.2

EDM

7 ×0.2

HEPAT

17 ×0.5

EE

16 ×0.5

PARAS

Citations per year, relative to A Goertz A Goertz (= 1×) peers Benedetto Simone

Countries citing papers authored by A Goertz

Since Specialization

Citations

This map shows the geographic impact of A Goertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Goertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Goertz more than expected).

Fields of papers citing papers by A Goertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Goertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Goertz. The network helps show where A Goertz may publish in the future.

Co-authorship network of co-authors of A Goertz

This figure shows the co-authorship network connecting the top 25 collaborators of A Goertz. A scholar is included among the top collaborators of A Goertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Goertz. A Goertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Sehouli, Jalid, et al.. (2010). Pegfilgrastim vs. Filgrastim zur Primärprophylaxe der febrilen Neutropenie bei Brustkrebspatientinnen nach Chemotherapie. DMW - Deutsche Medizinische Wochenschrift. 135(9). 385–389. 9 indexed citations

2.

Goertz, A, et al.. (2006). PIN6 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN GERMANY. Value in Health. 9(6). A300–A300. 2 indexed citations

3.

Shearer, Arran, A Bagust, Andreas Liebl, Oliver Schoeffski, & A Goertz. (2006). Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany. PharmacoEconomics. 24(S1). 35–48. 8 indexed citations

4.

Hammerschmidt, Thomas, et al.. (2003). Validation of Health Economic Models: The Example of EVITA. Value in Health. 6(5). 551–559. 33 indexed citations

5.

Banz, Kurt, Stefan Wagenpfeil, A. Neiß, et al.. (2003). The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 21(11-12). 1256–1267. 75 indexed citations

6.

Shearer, A, et al.. (2003). DB3 COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY. Value in Health. 6(6). 607–607. 1 indexed citations

7.

Wagenpfeil, Stefan, et al.. (2002). Bootstrap Confidence Intervals for Costs-of-Illness of Type 2 Diabetes Mellitus in Germany. Value in Health. 5(5). 398–404. 6 indexed citations

8.

Neiss, A, et al.. (2002). Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2^TM study. Experimental and Clinical Endocrinology & Diabetes. 110(1). 10–16. 68 indexed citations

9.

Wutzler, Peter, et al.. (2002). Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Medical Microbiology and Immunology. 191(2). 89–96. 33 indexed citations

10.

Stammer, Holger, et al.. (2000). PDB3: USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES. Value in Health. 3(5). 338–339. 1 indexed citations

11.

Goertz, A, et al.. (2000). [Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year?].. PubMed. 142(23). 39–42. 5 indexed citations

12.

Banz, Kurt, et al.. (2000). ID3: PRELIMINARY EVALUATION OF THE CLINICAL AND ECONOMIC BENEFITS OF UNIVERSAL VARICELLA VACCINATION OF CHILDREN IN GERMANY. Value in Health. 3(5). 297–297. 2 indexed citations

13.

Goertz, A, et al.. (1999). ED3: DEALING WITH CO-MORBIDITY AND RARE COMPLICATIONS IN A DIABETES TYPE 2 COST OF ILLNESS STUDY. Value in Health. 2(5). 370–370. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact